



**FOR IMMEDIATE RELEASE**

**Contact:**

For SI-BONE, Inc:  
Jeff Polack, Marketing  
408-725-9070, ext. 21  
[jeffp@si-bone.com](mailto:jeffp@si-bone.com)

SI-BONE, Inc. unveils 4.0mm diameter iFuse™ Implant device

**Smaller implant size allows expanded minimally invasive treatment opportunities for the sacroiliac joint using the iFuse Implant System™**

Cupertino, California, Feb. 9 -- SI-BONE, Inc. (Cupertino, California) announced today that it has launched a, smaller 4.0mm size offering of their iFuse Implant System for minimally invasive fixation of the sacroiliac (SI) joint.

SI-BONE currently has the 7.0mm iFuse in 30, 35, 40, 45, 50 and 55mm lengths. The new 4.0mm iFuse implant will be available in 30, 35, 40 and 45mm lengths. "This new line of smaller sizes, which has recently been cleared for marketing in the US, facilitates surgical cases where bone space is limited. Typically the company recommends using three seven (7.0mm) implants for each patient to maximize implant surface contact with bone. In some cases, space is limited and only two of the larger implants can be placed. We can now offer surgeons the option of using a smaller implant for the third iFuse implant. The 4mm implant choice is an important one for surgeons to have to ensure proper spacing and placement," according to Jeffrey Polack, Vice President of Marketing and Clinical for SI-BONE.

Leonard Rudolf, MD, added, "We're very pleased that SI-BONE is releasing the 4.0mm iFuse implant as an addition to its minimally invasive iFuse System product line for treatment of SI Joint dysfunction. I have performed well over a dozen SI-BONE surgeries and this newer implant is a clinically useful addition to the product line."

The company has recently launched its nationwide training program for surgeons and physiatrists, and plans to train more than 150 clinicians in 2010. Surgeries are being performed throughout the United States in locations such as Las Vegas NV, St Albans Vermont, Louisville KY, Reno NV, Jacksonville FL, and San Diego CA.

In response to increasing awareness of SI Joint dysfunction as a debilitating symptom generator, SI-BONE, Inc. developed an innovative, patented, intramedullary implant to treat the SI Joint. The company is also planning a post-market multicenter study to determine its effect over time on SI Joint pathology and on symptoms associated with SI Joint dysfunction.

The iFuse Implant System is a commercially available device in the US intended for fracture fixation of large bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The iFuse procedure uses a minimal incision for delivery and implantation of small, titanium implants. The implants are coated with a porous plasma spray that acts as an interference surface, designed to help decrease implant motion. These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional pins or screws used to surgically fix boney structures. This implant technology from SI-BONE has been previously used successfully in approximately 1,000 cases of dysfunctional foot joints.

###

**About SI-BONE, Inc.**

SI-BONE, Inc. (Cupertino, California) is a leading spinal medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to sacroiliac (SI) joint pathology. The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of SI Joint pathology. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.